StratX® Lung Analysis Report
Treat Severe Emphysema with Confidence
The StratX Lung Analysis Report is a cloud-based quantitative computed tomography (CT) analysis service that supports Zephyr® Valve patient selection and clinical outcome optimization.*
Target Lobe Selection
StratX Report presents fissure completeness, destruction score, and inspiratory volumes to allow identification of target lobes that are good candidates for treatment with Zephyr Valves – the most rigorously studied minimally-invasive treatment for severe emphysema. Lung volume reduction with Zephyr Valves is proven to improve patients’ breathing function, exercise capacity, and quality of life.1-3
StratX Report Features
LungTraXTM Platform enables you to:
-
Screen treatment candidates non-invasively
-
Choose between multiple potential treatment targets if applicable
-
Enhance case planning and optimise procedure time
- Post-treatment analysis of Zephyr Valve procedure to ensure optimal valve placement
-
Educate referrers about the optimal candidate for Zephyr Valve therapy
- Educate patients using user-friendly reports
How to Interpret a StratX Report
-
- StratX Report provides a non-invasive radiological assessment to determine a patient’s candidacy for Zephyr Valves.*
- StratX Report contains tabulated lobar data on:
- Fissure completeness
- Destruction score
- Volume
-
- Fissure completeness is a demonstrated predictor of Zephyr Valve success.4 Fissure completeness key:
- For fissure completeness scores of >80%, fissure integrity should be confirmed using Pulmonx’s
- Chartis® Pulmonary Assessment System to ensure that the target lobe is negative for collateral ventilation
- A fissure completeness score of <80% indicates the presence of collateral ventilation in that lobe and the lobe should not be considered for treatment with Zephyr Valves
-
- Lobar Destruction Score values of >50% at -910 HU were inclusion criteria for various Zephyr Valves clinical trials
- Lobar Destruction Score values of <50% at -910 HU are generally not considered as potential targets
-
- Inspiration Volume represents the volume of each lobe in millilitres
- Inspiration volume helps identify the most hyperinflated lobe targets
Physicians’ Feedback about Stratx Report
StratX Post-Treatment Report Benefits
If patients report loss of benefit or no improvement after treatment, valve adjustment via re-bronchoscopy is recommended and has demonstrated to improve patient outcomes.5 A StratX post-treatment report can be used to confirm valve placement, identify occluded and non-occluded airways, quantify target lobe volume reduction (TLVR).
Get in touch with us to find out more.
References
Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.
1. Criner, GJ, Sue, R, Wright, S, Dransfield, M, Rivas-Perez, H, Wiese, T, Sciurba, FC, Shah, PL, Wahidi, MM, de Oliveira, HG, & Morrissey, B. A multicenter randomized controlled trial of Zephyr® Endobronchial Valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med, 2018; 198(9), 1151–1164 et données internes sur la Valve Zephyr®.
2. Valipour, A, Slebos, DJ, Herth, F, Darwiche, K, Wagner, M, Ficker, JH, & Eberhardt, R. Endobronchial Valve therapy in patients with homogeneous emphysema. Résultats de l’étude IMPACT. Am J Respir Crit Care Med, 2016; 194(9), 1073–1082 et données internes.
3. Kemp, SV, Slebos, DJ, Kirk, A, Kornaszewska, M, Carron, K, Ek, L, & Briault, A. A multicenter randomized controlled trial of Zephyr Endobronchial Valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med, 2017; 196(12), 1535–1543.
4. Herth, FJ, Noppen, M, Valipour, A, Leroy, S, Vergnon, JM, Ficker, JH & Ernst, A. Efficacy predictors of lung volume reduction with Zephyr Valves in a European cohort. Eur Respir J, 2012; 39(6), 1334–1342.
5. Slebos, DJ, Shah, PL, Herth, FJ & Valipour, A. Endobronchial Valves for endoscopic lung volume reduction: best practice recommendations from expert panel on endoscopic lung volume reduction. Respir, 2017;93(2), 138-150.
* StratX and LungTraX are visualization tools that aid in the display of CT analysis results from Thirona’s LungQ® software, which is a CE-marked Class IIb device under EU MDR (EU) 2017/745 (DEKRA Certification B.V., Notified Body 0344). StratX and LungTraX do not perform CT analysis, diagnosis, or clinical assessment.
Refer to Thirona’s LungQ Instructions for Use for safety information and indications.
EMEA-EN-2325-v2
